Compare CURV & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CURV | MDXH |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.4M | 203.4M |
| IPO Year | 2021 | 2021 |
| Metric | CURV | MDXH |
|---|---|---|
| Price | $1.12 | $3.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $1.59 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 406.5K | 191.1K |
| Earning Date | 12-03-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,039,486,000.00 | $103,069,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | N/A | $22.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.68 |
| 52 Week Low | $1.08 | $1.35 |
| 52 Week High | $7.19 | $5.33 |
| Indicator | CURV | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 42.64 |
| Support Level | $1.08 | $3.40 |
| Resistance Level | $1.46 | $3.74 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 10.67 | 81.43 |
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.